{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:28:10Z","timestamp":1791160090517,"version":"4.1.0"},"reference-count":65,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1016\/j.clinthera.2014.12.020","type":"journal-article","created":{"date-parts":[[2015,2,7]],"date-time":"2015-02-07T17:48:29Z","timestamp":1423331309000},"page":"668-680","source":"Crossref","is-referenced-by-count":69,"title":["Therapeutic Development in Amyotrophic Lateral Sclerosis"],"prefix":"10.1016","volume":"37","author":[{"given":"Monica","family":"Bucchia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnese","family":"Ramirez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Parente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Simone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Nizzardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Magri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Dametti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Corti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2014.12.020_bib1","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.expneurol.2014.02.021","article-title":"The past, present and future of stem cell clinical trials for ALS","volume":"262","author":"Thomsen","year":"2014","journal-title":"Exp Neurol"},{"key":"10.1016\/j.clinthera.2014.12.020_bib2","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.neuron.2011.09.011","article-title":"Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS","volume":"72","author":"DeJesus-Hernandez","year":"2011","journal-title":"Neuron"},{"key":"10.1016\/j.clinthera.2014.12.020_bib3","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/nrneurol.2011.152","article-title":"Molecular pathways of motor neuron injury in amyotrophic lateral sclerosis","volume":"7","author":"Ferraiuolo","year":"2011","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.clinthera.2014.12.020_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.freeradbiomed.2013.03.018","article-title":"Mitochondrial diseases of the brain","volume":"63","author":"Chaturvedi","year":"2013","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.clinthera.2014.12.020_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.brainres.2012.01.046","article-title":"Effects of dexpramipexole on brain mitochondrial conductances and cellular bioenergetic efficiency","volume":"1446","author":"Alavian","year":"2012","journal-title":"Brain Res"},{"key":"10.1016\/j.clinthera.2014.12.020_bib6","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/S1474-4422(13)70221-7","article-title":"Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis [6]: a randomised, double-blind, phase 3 trial","volume":"12","author":"Cudkowicz","year":"2013","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.clinthera.2014.12.020_bib7","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/S1474-4422(13)70224-2","article-title":"The murky path to drug discovery in ALS becomes clearer","volume":"12","author":"Gordon","year":"2013","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.clinthera.2014.12.020_bib8","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.pneurobio.2010.06.008","article-title":"Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity","volume":"92","author":"Weinreb","year":"2010","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.clinthera.2014.12.020_bib9","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1007\/s00415-004-0481-5","article-title":"Rasagiline alone and in combination with riluzole prolongs survival in an ALS mouse model","volume":"251","author":"Waibel","year":"2004","journal-title":"J Neurol"},{"key":"10.1016\/j.clinthera.2014.12.020_bib10","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/S1474-4422(09)70062-6","article-title":"Neuroinflammation in Parkinson\u02bcs disease: a target for neuroprotection?","volume":"8","author":"Hirsch","year":"2009","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.clinthera.2014.12.020_bib11","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.neuron.2009.08.039","article-title":"Immune activation in brain aging and neurodegeneration: too much or too little?","volume":"64","author":"Lucin","year":"2009","journal-title":"Neuron"},{"key":"10.1016\/j.clinthera.2014.12.020_bib12","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.mcn.2012.10.008","article-title":"Inflammation and neurovascular changes in amyotrophic lateral sclerosis","volume":"53","author":"Evans","year":"2013","journal-title":"Mol Cell Neurosci"},{"key":"10.1016\/j.clinthera.2014.12.020_bib13","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.neuint.2006.04.003","article-title":"Peroxisome proliferator-activated receptor agonist regulation of glial activation: relevance to CNS inflammatory disorders","volume":"49","author":"Drew","year":"2006","journal-title":"Neurochem Int"},{"key":"10.1016\/j.clinthera.2014.12.020_bib14","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1126\/science.1086071","article-title":"Wild-type nonneuronal cells extend survival of SOD1 mutant motor neurons in ALS mice","volume":"302","author":"Clement","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.clinthera.2014.12.020_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2014.05.015","article-title":"Glial cells in amyotrophic lateral sclerosis","author":"Philips","year":"2014","journal-title":"Exp Neurol"},{"key":"10.1016\/j.clinthera.2014.12.020_bib16","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s00018-013-1480-4","article-title":"Cellular therapy to target neuroinflammation in amyotrophic lateral sclerosis","volume":"71","author":"Rizzo","year":"2014","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.clinthera.2014.12.020_bib17","first-page":"213","article-title":"A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya)","volume":"12","author":"Chun","year":"2011","journal-title":"Discov Med"},{"key":"10.1016\/j.clinthera.2014.12.020_bib18","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/ng.557","article-title":"From transcriptome analysis to therapeutic anti-CD40L treatment in the SOD1 model of amyotrophic lateral sclerosis","volume":"42","author":"Lincecum","year":"2010","journal-title":"Nat Genet"},{"key":"10.1016\/j.clinthera.2014.12.020_bib19","first-page":"305","article-title":"Tocilizumab attenuates inflammation in ALS patients through inhibition of IL6 receptor signaling","volume":"1","author":"Mizwicki","year":"2012","journal-title":"Am J Neurodegener Dis"},{"key":"10.1016\/j.clinthera.2014.12.020_bib20","first-page":"129","article-title":"Tocilizumab infusion therapy normalizes inflammation in sporadic ALS patients","volume":"2","author":"Fiala","year":"2013","journal-title":"Am J Neurodegener Dis"},{"key":"10.1016\/j.clinthera.2014.12.020_bib21","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.neurobiolaging.2013.11.019","article-title":"Autophagy in aging and neurodegenerative diseases: implications for pathogenesis and therapy","volume":"35","author":"Tan","year":"2014","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.clinthera.2014.12.020_bib22","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1073\/pnas.0708022105","article-title":"Lithium delays progression of amyotrophic lateral sclerosis","volume":"105","author":"Fornai","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clinthera.2014.12.020_bib23","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1124\/mol.106.030676","article-title":"Concurrent administration of Neu2000 and lithium produces marked improvement of motor neuron survival, motor function, and mortality in a mouse model of amyotrophic lateral sclerosis","volume":"71","author":"Shin","year":"2007","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.clinthera.2014.12.020_bib24","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S1474-4422(13)70037-1","article-title":"Lithium in patients with amyotrophic lateral sclerosis [24]: a phase 3 multicentre, randomised, double-blind, placebo-controlled trial","volume":"12","author":"Morrison","year":"2013","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.clinthera.2014.12.020_bib25","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S1474-4422(10)70068-5","article-title":"Northeast and Canadian Amyotrophic Lateral Sclerosis consortia. Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial","volume":"9","author":"Aggarwal","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.clinthera.2014.12.020_bib26","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1212\/WNL.0b013e3181ed9e7c","article-title":"Lithium carbonate in amyotrophic lateral sclerosis: lack of efficacy in a dose-finding trial","volume":"75","author":"Chi\u00f2","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2014.12.020_bib27","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1212\/WNL.0b013e31822dc7a5","article-title":"Phase II screening trial of lithium carbonate in amyotrophic lateral sclerosis: examining a more efficient trial design","volume":"77","author":"Miller","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2014.12.020_bib28","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/jnnp-2011-302021","article-title":"Lithium lacks effect on survival in amyotrophic lateral sclerosis: a phase IIb randomised sequential trial","volume":"83","author":"Verstraete","year":"2012","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.clinthera.2014.12.020_bib29","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/nbt.1837","article-title":"Accelerated clinical discovery using self-reported patient data collected online and a patient-matching algorithm","volume":"29","author":"Wicks","year":"2011","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.clinthera.2014.12.020_bib30","doi-asserted-by":"crossref","first-page":"e7258","DOI":"10.1371\/journal.pone.0007258","article-title":"Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT","volume":"4","author":"Dubreuil","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.clinthera.2014.12.020_bib31","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/glia.22601","article-title":"Rho kinase inhibition modulates microglia activation and improves survival in a model of amyotrophic lateral sclerosis","volume":"62","author":"T\u00f6nges","year":"2014","journal-title":"Glia"},{"key":"10.1016\/j.clinthera.2014.12.020_bib32","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/bph.12277","article-title":"Fasudil, a rho kinase inhibitor, limits motor neuron loss in experimental models of amyotrophic lateral sclerosis","volume":"170","author":"Takata","year":"2013","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.clinthera.2014.12.020_bib33","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3006767","article-title":"Oral treatment targeting the unfolded protein response prevents neurodegeneration and clinical disease in prion-infected mice","volume":"5","author":"Moreno","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.clinthera.2014.12.020_bib34","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/ng.2853","article-title":"Therapeutic modulation of eIF2\u03b1 phosphorylation rescues TDP-43 toxicity in amyotrophic lateral sclerosis disease models","volume":"46","author":"Kim","year":"2014","journal-title":"Nat Genet"},{"key":"10.1016\/j.clinthera.2014.12.020_bib35","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.expneurol.2007.03.004","article-title":"Inhibition of glycogen synthase kinase-3 suppresses the onset of symptoms and disease progression of G93A-SOD1 mouse model of ALS","volume":"205","author":"Koh","year":"2007","journal-title":"Exp Neurol"},{"key":"10.1016\/j.clinthera.2014.12.020_bib36","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1038\/nn1885","article-title":"Non-cell autonomous effect of glia on motor neurons in an embryonic stem cell-based ALS model","volume":"10","author":"Di Giorgio","year":"2007","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.clinthera.2014.12.020_bib37","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1074\/jbc.274.4.2118","article-title":"A novel human STE20-related protein kinase, HGK, that specifically activates the c-Jun N-terminal kinase signaling pathway","volume":"274","author":"Yao","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1016\/j.clinthera.2014.12.020_bib38","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.stem.2013.04.003","article-title":"A small molecule screen in stem-cell-derived motor neurons identifies a kinase inhibitor as a candidate therapeutic for ALS","volume":"12","author":"Yang","year":"2013","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.clinthera.2014.12.020_bib39","doi-asserted-by":"crossref","first-page":"430","DOI":"10.3109\/17482968.2011.585163","article-title":"Anti-superoxide dismutase antibodies are associated with survival in patients with sporadic amyotrophic lateral sclerosis","volume":"12","author":"van Blitterswijk","year":"2011","journal-title":"Amyotroph Lateral Scler"},{"key":"10.1016\/j.clinthera.2014.12.020_bib40","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1172\/JCI25424","article-title":"Antisense oligonucleotide therapy for neurodegenerative disease","volume":"116","author":"Smith","year":"2006","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clinthera.2014.12.020_bib41","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S1474-4422(13)70061-9","article-title":"An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study","volume":"12","author":"Miller","year":"2013","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.clinthera.2014.12.020_bib42","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.neuron.2013.10.015","article-title":"RNA toxicity from the ALS\/FTD C9ORF72 expansion is mitigated by antisense intervention","volume":"80","author":"Donnelly","year":"2013","journal-title":"Neuron"},{"key":"10.1016\/j.clinthera.2014.12.020_bib43","doi-asserted-by":"crossref","first-page":"E4530","DOI":"10.1073\/pnas.1318835110","article-title":"Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration","volume":"110","author":"Lagier-Tourenne","year":"2013","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.clinthera.2014.12.020_bib44","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3007529","article-title":"Targeting RNA foci in iPSC-derived motor neurons from ALS patients with a C9ORF72 repeat expansion","volume":"5","author":"Sareen","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.clinthera.2014.12.020_bib45","doi-asserted-by":"crossref","first-page":"E4968","DOI":"10.1073\/pnas.1315438110","article-title":"RAN proteins and RNA foci from antisense transcripts in C9ORF72 ALS and frontotemporal dementia","volume":"110","author":"Zu","year":"2013","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.clinthera.2014.12.020_bib46","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1039\/C3OB42023J","article-title":"Methods to enable the design of bioactive small molecules targeting RNA","volume":"12","author":"Disney","year":"2014","journal-title":"Org Biomol Chem"},{"key":"10.1016\/j.clinthera.2014.12.020_bib47","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/nrneurol.2011.191","article-title":"Translational stem cell therapy for amyotrophic lateral sclerosis","volume":"8","author":"Boulis","year":"2011","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.clinthera.2014.12.020_bib48","doi-asserted-by":"crossref","first-page":"e25968","DOI":"10.1371\/journal.pone.0025968","article-title":"Human glial-restricted progenitor transplantation into cervical spinal cord of the SOD1 mouse model of ALS","volume":"6","author":"Lepore","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.clinthera.2014.12.020_bib49","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.1073\/pnas.1300398110","article-title":"Astrocytes pathology and the absence of non-cell autonomy in an induced pluripotent stem cells model of TDP-43 proteinopathy","volume":"110","author":"Serio","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clinthera.2014.12.020_bib50","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.neuron.2014.01.011","article-title":"Necroptosis Drives Motor Neuron Death in Models of Both Sporadic and Familial ALS","volume":"81","author":"Re","year":"2014","journal-title":"Neuron"},{"key":"10.1016\/j.clinthera.2014.12.020_bib51","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.tins.2008.01.006","article-title":"Combining growth factor and stem cell therapy for amyotrophic lateral sclerosis","volume":"31","author":"Suzuki","year":"2008","journal-title":"Trends Neurosci"},{"key":"10.1016\/j.clinthera.2014.12.020_bib52","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.neuron.2013.10.037","article-title":"Neural stem cells: generating and regenerating the brain","volume":"80","author":"Gage","year":"2013","journal-title":"Neuron"},{"key":"10.1016\/j.clinthera.2014.12.020_bib53","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1093\/hmg\/ddt425","article-title":"Minimally invasive transplantation of iPSC-derived ALDHhiSSCloVLA4+ neural stem cells effectively improves the phenotype of an amyotrophic lateral sclerosis model","volume":"23","author":"Nizzardo","year":"2014","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.clinthera.2014.12.020_bib54","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3004579","article-title":"Multimodal actions of neural stem cells in a mouse model of ALS: a meta-analysis","volume":"4","author":"Teng","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.clinthera.2014.12.020_bib55","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1227\/NEU.0b013e31825ca05f","article-title":"Intraspinal stem cell transplantation in amyotrophic lateral sclerosis: a phase I safety trial, technical note, and lumbar safety outcomes","volume":"71","author":"Riley","year":"2012","journal-title":"Neurosurgery"},{"key":"10.1016\/j.clinthera.2014.12.020_bib56","doi-asserted-by":"crossref","first-page":"C1049","DOI":"10.1152\/ajpcell.00431.2008","article-title":"Voltage-gated sodium channel modulation by sigma-receptors in cardiac myocytes and heterologous systems","volume":"296","author":"Johannessen","year":"2009","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.clinthera.2014.12.020_bib57","doi-asserted-by":"crossref","first-page":"295","DOI":"10.14336\/AD.2013.0400295","article-title":"Amyotrophic Lateral Sclerosis: An update for 2013 Clinical Features, Pathophysiology, Management and Therapeutic Trials","volume":"4","author":"Gordon","year":"2013","journal-title":"Aging Dis"},{"key":"10.1016\/j.clinthera.2014.12.020_bib58","doi-asserted-by":"crossref","first-page":"e97803","DOI":"10.1371\/journal.pone.0097803","article-title":"Safety, pharmacokinetic, and functional effects of the nogo-a monoclonal antibody in amyotrophic lateral sclerosis: a randomized, first-in-human clinical trial","volume":"9","author":"Meininger","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.clinthera.2014.12.020_bib59","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/j.1600-0404.1992.tb05103.x","article-title":"Treatment of myotonia with antiarrhythmic drugs","volume":"86","author":"Kwieci\u0144ski","year":"1992","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.clinthera.2014.12.020_bib60","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/nn1876","article-title":"Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons","volume":"10","author":"Nagai","year":"2007","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.clinthera.2014.12.020_bib61","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1152\/jn.00500.2012","article-title":"Mutant SOD1-expressing astrocytes release toxic factors that trigger motoneuron death by inducing hyperexcitability","volume":"109","author":"Fritz","year":"2013","journal-title":"J Neurophysiol"},{"key":"10.1016\/j.clinthera.2014.12.020_bib62","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/nm.2618","article-title":"Activation of fast skeletal muscle troponin as a potential therapeutic approach for treating neuromuscular diseases","volume":"18","author":"Russell","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.clinthera.2014.12.020_bib63","doi-asserted-by":"crossref","first-page":"574","DOI":"10.3109\/21678421.2013.822517","article-title":"A study to evaluate safety and tolerability of repeated doses of tirasemtiv in patients with amyotrophic lateral sclerosis","volume":"14","author":"Shefner","year":"2013","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"10.1016\/j.clinthera.2014.12.020_bib64","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1038\/nm.2901","article-title":"EPHA4 is a disease modifier of amyotrophic lateral sclerosis in animal models and in humans","volume":"18","author":"Van Hoecke","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.clinthera.2014.12.020_bib65","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1042\/BJ20120408","article-title":"Distinctive binding of three antagonistic peptides to the ephrin-binding pocket of the EphA4 receptor","volume":"445","author":"Lamberto","year":"2012","journal-title":"Biochem J"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291815000107?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291815000107?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,25]],"date-time":"2018-09-25T06:56:49Z","timestamp":1537858609000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291815000107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":65,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["S0149291815000107"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2014.12.020","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2015,3]]}}}